Journal of Clinical Oncology, Vol 6, 1001-1007, Copyright © 1988 by American Society of Clinical Oncology
Astrocytoma in children: 14 years' experience at Stanford University Medical Center
SY Woo, SS Donaldson and RS Cox
Department of Therapeutic Radiology, Stanford University Medical Center, CA 94305.
Between January 1, 1971 and December 31, 1984, 50 children (31 males, 19
females) ages 3 1/2 months to 18 years with primary CNS astrocytoma were
seen in the Department of Therapeutic Radiology, Stanford University
Medical Center. The actuarial survival and freedom from relapse (FFR) for
the treated group is 46%, with a median follow-up of 7.2 years and a
maximum follow-up of 14 years. The majority of relapses occurred within the
first 2 years of diagnosis, and all relapses occurred at or adjacent to the
initial site of tumor. Multivariate analysis revealed that factors
correlated with poor survival are high histologic grade (including presence
of necrosis) and primary tumor in the brain stem, while the only important
prognostic factor associated with an adverse FFR is high histologic grade.
Age, sex, degree of surgical resection, and total radiation dose to the
tumor are not correlated with outcome. Patients with high-grade tumor were
selected to receive whole brain irradiation and/or adjuvant chemotherapy;
therefore, the findings of apparent poor prognosis associated with whole
brain irradiation and adjuvant chemotherapy actually reflect patient
selection. Current therapy is adequate for only half of children with
astrocytoma. Thus, continued development of innovative therapies is
indicated, particularly for those children with adverse prognostic factors.